By Dean Seal

Shares of Precigen jumped after the company said the first full quarter of sales for its flagship drug went better than expected.

The stock gained 16% to $4.81 on Thursday, pushing shares back in positive territory year to date.

The biopharmaceutical company said its drug Papzimeos, which is approved for adults with recurrent respiratory papillomatosis, had strong momentum through the first three months of the year.

The treatment generated $21.6 million in product revenue. Total company revenue jumped to $23.3 million from $1.3 million, ahead of analyst targets for $20.8 million, according to FactSet.

The big jump in revenue allowed Precigen to shrink its quarterly loss to $7.9 million, or 2 cents a share, from $54.2 million, or 18 cents a share, in the same quarter a year earlier.

Given the cash inflows and anticipated revenue ahead, Precigen expects to break even on cash flow by the end of this year, it said.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

May 14, 2026 12:38 ET (16:38 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.